Innate Pharma S.A. (IPHA) 10-Year Financial Performance & Capital Metrics

IPHA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutInnate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.Show more

Revenue $13M -75.7%
EBITDA -$50M -554.3%
Net Income -$49M -553.5%
EPS (Diluted) -0.61 -577.8%
Gross Margin 100% +823.7%
EBITDA Margin -392.85% -2590.6%
Operating Margin -408.64% -1574.1%
Net Margin -391.97% -2587.4%
ROE -162.91% -1041.1%
ROIC -
Debt/Equity 3.51 +356.5%
Interest Coverage -91.12 -360.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 3.6% through buybacks

✗Weaknesses

✗High debt to equity ratio of 3.5x
✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 28.8% over 5 years
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y30.12%

5Y-28.8%

3Y1.38%

TTM-61.2%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM6.28%

EPS CAGR

10Y-

5Y-

3Y-

TTM8.62%

ROCE

10Y Avg-14.17%

5Y Avg-22%

3Y Avg-29.7%

Latest-48.29%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	17.91M	56.16M	32.63M	79.89M	68.97M	69.77M	12.11M	57.67M	51.9M	12.62M
Revenue Growth %	18.74%	2.14%	-0.42%	1.45%	-0.14%	0.01%	-0.83%	3.76%	-0.1%	-0.76%
Cost of Goods Sold+	29.91M	48.63M	67M	69.56M	45.16M	49.71M	47M	51.66M	56.02M	0
COGS % of Revenue	1.67%	0.87%	2.05%	0.87%	0.65%	0.71%	3.88%	0.9%	1.08%	-
Gross Profit+	-12M	7.53M	-34.37M	10.34M	23.82M	20.07M	-22.3M	6.01M	5.62M	12.62M
Gross Margin %	-0.67%	0.13%	-1.05%	0.13%	0.35%	0.29%	-1.84%	0.1%	0.11%	1%
Gross Profit Growth %	-0.07%	1.63%	-5.56%	1.3%	1.3%	-0.16%	-2.11%	1.27%	-0.07%	1.25%
Operating Expenses+	28.68M	48.59M	72.61M	74.75M	50.87M	18.99M	25.52M	63.44M	18.29M	64.2M
OpEx % of Revenue	1.6%	0.87%	2.23%	0.94%	0.74%	0.27%	2.11%	1.1%	0.35%	5.09%
Selling, General & Admin	5.88M	9.33M	16.18M	19.25M	49.58M	18.99M	25.52M	14.47M	11.75M	11.93M
SG&A % of Revenue	0.33%	0.17%	0.5%	0.24%	0.72%	0.27%	2.11%	0.25%	0.23%	0.95%
Research & Development	29.91M	48.63M	67M	69.56M	1.6M	49.71M	47M	51.66M	56.02M	51.98M
R&D % of Revenue	1.67%	0.87%	2.05%	0.87%	0.02%	0.71%	3.88%	0.9%	1.08%	4.12%
Other Operating Expenses	-7.11M	-9.37M	-10.57M	-14.06M	-309K	-49.71M	-47M	-2.7M	-49.48M	283K
Operating Income+	-10.77M	7.57M	-39.98M	5.15M	-27.05M	1.08M	-47.83M	-57.42M	-12.67M	-51.58M
Operating Margin %	-0.6%	0.13%	-1.23%	0.06%	-0.39%	0.02%	-3.95%	-1%	-0.24%	-4.09%
Operating Income Growth %	0.46%	1.7%	-6.28%	1.13%	-6.26%	1.04%	-45.32%	-0.2%	0.78%	-3.07%
EBITDA+	-8.12M	10.83M	-35.59M	12.55M	-10.52M	13.3M	-43.23M	-12.02M	-7.58M	-49.58M
EBITDA Margin %	-0.45%	0.19%	-1.09%	0.16%	-0.15%	0.19%	-3.57%	-0.21%	-0.15%	-3.93%
EBITDA Growth %	0.54%	2.33%	-4.28%	1.35%	-1.84%	2.26%	-4.25%	0.72%	0.37%	-5.54%
D&A (Non-Cash Add-back)	2.65M	3.26M	4.4M	7.4M	16.53M	12.23M	4.6M	45.41M	5.09M	1.99M
EBIT	-6.57M	13.06M	-39.98M	5.15M	1.57M	1.08M	-47.83M	-57.68M	-6.93M	-48.91M
Net Interest Income+	-112K	686K	1.08M	1.3M	1.43M	223K	15K	258K	2.54M	1.87M
Interest Income	27K	0	1.25M	1.58M	1.62M	564K	327K	546K	3.18M	2.44M
Interest Expense	139K	124K	113K	102K	204K	341K	312K	288K	640K	566K
Other Income/Expense	4.07M	5.37M	-8.03M	-2.43M	6.29M	-1.91M	2.35M	-547K	5.1M	2.1M
Pretax Income+	-6.71M	12.94M	-48.02M	2.72M	-20.76M	-829K	-45.48M	-57.97M	-7.57M	-49.47M
Pretax Margin %	-0.37%	0.23%	-1.47%	0.03%	-0.3%	-0.01%	-3.75%	-1.01%	-0.15%	-3.92%
Income Tax+	0	301K	368K	-333K	206K	0	0	0	0	0
Effective Tax Rate %	1%	0.98%	1.01%	1.12%	1%	77.18%	1.16%	1%	1%	1%
Net Income+	-6.71M	12.64M	-48.38M	3.05M	-20.76M	-63.98M	-52.81M	-58.1M	-7.57M	-49.47M
Net Margin %	-0.37%	0.23%	-1.48%	0.04%	-0.3%	-0.92%	-4.36%	-1.01%	-0.15%	-3.92%
Net Income Growth %	0.66%	2.88%	-4.83%	1.06%	-7.81%	-2.08%	0.17%	-0.1%	0.87%	-5.54%
Net Income (Continuing)	-6.71M	12.64M	-48.38M	3.05M	0	-829K	-45.48M	-57.97M	-7.57M	-49.47M
Discontinued Operations	0	0	0	0	0	-63.16M	-7.33M	-131K	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.13	0.23	-0.89	0.05	-0.31	-0.01	-0.57	-0.73	-0.09	-0.61
EPS Growth %	0.67%	2.77%	-4.87%	1.06%	-6.97%	0.97%	-53.29%	-0.28%	0.88%	-5.78%
EPS (Basic)	-0.13	0.23	-0.89	0.05	-0.31	-0.01	-0.57	-0.73	-0.09	-0.61
Diluted Shares Outstanding	53.4M	53.87M	54.35M	58.78M	66.91M	78.93M	79.54M	79.64M	84.11M	81.05M
Basic Shares Outstanding	51.58M	53.87M	54.35M	58.78M	66.91M	78.93M	79.54M	79.59M	84.11M	81.05M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	252.13M	230.08M	137.52M	319.64M	237.6M	173.33M	138.26M	139.83M	148.01M	85.74M
Cash & Short-Term Investments	235.91M	197.69M	116.11M	167.53M	218.87M	151.64M	119.84M	101.48M	92.46M	80.77M
Cash Only	152.87M	175.91M	99.37M	152.31M	202.89M	136.79M	103.76M	84.22M	70.61M	66.4M
Short-Term Investments	83.04M	21.78M	16.74M	15.22M	15.98M	14.85M	16.08M	17.26M	21.85M	14.37M
Accounts Receivable	9.95M	25.55M	15.08M	146.64M	2.82M	11.33M	1.66M	3.14M	46.49M	1.64M
Days Sales Outstanding	202.78	166.08	168.72	669.94	14.9	59.25	50.02	19.88	326.94	47.52
Inventory	278K	513K	6.33M	0	5.6M	3.28M	0	0	0	0
Days Inventory Outstanding	3.39	3.85	34.47	-	45.26	24.1	-	-	-	-
Other Current Assets	0	0	0	0	4.92M	-860K	11.81M	27.88M	0	0
Total Non-Current Assets+	53.83M	51.5M	117.5M	131.57M	163.76M	134.09M	129.24M	68.03M	27.18M	25.32M
Property, Plant & Equipment	6.3M	9.09M	10.73M	10.22M	11.67M	11.69M	10.17M	8.54M	6.32M	5.13M
Fixed Asset Turnover	2.84x	6.18x	3.04x	7.82x	5.91x	5.97x	1.19x	6.75x	8.21x	2.46x
Goodwill	0	0	0	0	0	1K	2K	-41M	0	0
Intangible Assets	9.73M	9.07M	46.19M	84.53M	96.97M	46.29M	44.19M	42.55M	416K	0
Long-Term Investments	37.79M	32.98M	60.47M	35.18M	37.01M	38.93M	39.88M	35.12M	9.8M	10.28M
Other Non-Current Assets	37.79M	355K	111K	87K	16.83M	30.09M	29.97M	14.25M	1.64M	9.9M
Total Assets+	305.96M	281.58M	255.02M	451.22M	401.36M	307.42M	267.5M	207.86M	175.19M	111.06M
Asset Turnover	0.06x	0.20x	0.13x	0.18x	0.17x	0.23x	0.05x	0.28x	0.30x	0.11x
Asset Growth %	2.37%	-0.08%	-0.09%	0.77%	-0.11%	-0.23%	-0.13%	-0.22%	-0.16%	-0.37%
Total Current Liabilities+	60.16M	76.44M	73.91M	196.74M	121.82M	45.49M	79.89M	41.34M	39.64M	32.98M
Accounts Payable	8.62M	15.6M	19.97M	28.58M	27.94M	20.73M	14.73M	13.66M	8.56M	7.92M
Days Payables Outstanding	105.18	117.09	108.79	149.96	225.8	152.22	114.38	96.48	55.78	-
Short-Term Debt	150K	375K	429K	394K	1.49M	1.36M	29.94M	1.26M	8.45M	8.44M
Deferred Revenue (Current)	-1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	616K
Other Current Liabilities	10.01M	4.67M	4.69M	71.62M	42.99M	10.11M	21.91M	19.02M	7.82M	7.65M
Current Ratio	4.19x	3.01x	1.86x	1.62x	1.95x	3.81x	1.73x	3.38x	3.73x	2.60x
Quick Ratio	4.19x	3.00x	1.78x	1.62x	1.90x	3.74x	1.73x	3.38x	3.73x	2.60x
Cash Conversion Cycle	100.99	52.85	94.41	-	-165.63	-68.87	-	-	-	-
Total Non-Current Liabilities+	173.73M	118.97M	95.16M	87.24M	62.12M	104.75M	80.17M	112.37M	83.65M	69.24M
Long-Term Debt	1.35M	1.05M	2.42M	2.03M	14.1M	14.19M	11.49M	38.93M	30.61M	22.18M
Capital Lease Obligations	1.78M	3.01M	2.1M	1.14M	2.49M	2.76M	2.01M	1.22M	350K	104K
Deferred Tax Liabilities	0	2.55M	3.63M	1.56M	1.29M	7.09M	5.03M	8.57M	9.01M	0
Other Non-Current Liabilities	170.59M	112.35M	3.63M	14.4M	3.9M	49.25M	36.23M	55.74M	39.07M	44.13M
Total Liabilities	233.89M	195.41M	169.07M	283.98M	183.94M	151.45M	160.06M	153.71M	132.29M	102.22M
Total Debt+	3.75M	5.33M	5.86M	4.52M	18.72M	19.09M	44.25M	42.25M	39.89M	31M
Net Debt	-149.12M	-170.58M	-93.5M	-147.79M	-184.16M	-117.7M	-59.51M	-41.97M	-30.71M	-35.4M
Debt / Equity	0.05x	0.06x	0.07x	0.03x	0.09x	0.12x	0.41x	0.78x	0.77x	3.51x
Debt / EBITDA	-	0.49x	-	0.36x	-	1.43x	-	-	-	-
Net Debt / EBITDA	-	-15.74x	-	-11.78x	-	-8.85x	-	-	-	-
Interest Coverage	-77.50x	61.06x	-353.83x	50.45x	-132.61x	3.16x	-153.29x	-199.39x	-19.80x	-91.12x
Total Equity+	72.07M	86.17M	85.96M	167.24M	217.42M	155.97M	107.44M	54.15M	51.9M	8.83M
Equity Growth %	-0.03%	0.2%	-0%	0.95%	0.3%	-0.28%	-0.31%	-0.5%	-0.04%	-0.83%
Book Value per Share	1.35	1.60	1.58	2.85	3.25	1.98	1.35	0.68	0.62	0.11
Total Shareholders' Equity	72.07M	86.17M	85.96M	167.24M	217.42M	155.97M	107.44M	54.15M	51.9M	8.83M
Common Stock	2.69M	2.7M	2.88M	3.2M	3.94M	3.95M	3.98M	4.01M	4.04M	4.19M
Retained Earnings	-116.23M	-103.59M	-151.98M	-134.79M	-155.67M	-220.46M	-272.21M	-330.32M	-336.89M	-386.36M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-730K	-503K	180K	-1.1M	-472K	355K	456K	819K	495K	27K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	207.91M	-36.85M	-48.06M	-32.53M	34.92M	-51.81M	-58.46M	-19.15M	-32.56M	-6.9M
Operating CF Margin %	11.61%	-0.66%	-1.47%	-0.41%	0.51%	-0.74%	-4.83%	-0.33%	-0.63%	-0.55%
Operating CF Growth %	12.47%	-1.18%	-0.3%	0.32%	2.07%	-2.48%	-0.13%	0.67%	-0.7%	0.79%
Net Income	-6.71M	12.64M	-48.38M	3.05M	-20.76M	-63.98M	-52.81M	-58.1M	-7.57M	-49.47M
Depreciation & Amortization	2.65M	3.26M	4.39M	7.4M	16.53M	56.8M	4.6M	45.41M	5.09M	1.99M
Stock-Based Compensation	1.01M	1.03M	9.83M	2.71M	3.83M	2.48M	2.62M	4.25M	4.26M	3.94M
Deferred Taxes	-586K	-2.61M	3.17M	1.16M	-4.14M	2.65M	-1.68M	0	0	0
Other Non-Cash Items	47K	-383K	-88K	253K	-774K	-544K	-1.29M	1.8M	-2.24M	-2.52M
Working Capital Changes	211.49M	-50.79M	-16.98M	-47.1M	40.25M	-49.2M	-9.88M	-12.5M	-32.09M	39.16M
Change in Receivables	-6.14M	-16.17M	10.98M	-130.7M	110.3M	-22.92M	3.39M	-4.2M	-13.67M	0
Change in Inventory	0	0	0	0	0	25.38M	-6.27M	0	0	0
Change in Payables	9.23M	7.89M	4.39M	34.34M	1.39M	-6.53M	-946K	-7.66M	-3.89M	0
Cash from Investing+	-122.3M	60.51M	-29.46M	24.28M	-62.12M	-13.37M	-917K	1.88M	20.63M	9.2M
Capital Expenditures	-7.4M	-9.39M	-6.03M	-1.43M	-65.4M	-11.28M	-1.33M	-1.12M	-351K	-391K
CapEx % of Revenue	0.41%	0.17%	0.18%	0.02%	0.95%	0.16%	0.11%	0.02%	0.01%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	972K	-8.04M	-3.06M	46K	1.28M	912K	406K	-1K	-1.79M	1K
Cash from Financing+	3.03M	-602K	915K	61.22M	77.77M	-1.14M	26.82M	-1.83M	-1.97M	-6.01M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	3.36M	69K	378K	8K	-159K	-251K	187K	0	395K	2.93M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	200.51M	-46.24M	-54.09M	-33.96M	-30.48M	-63.09M	-59.79M	-20.28M	-34.91M	-7.29M
FCF Margin %	11.2%	-0.82%	-1.66%	-0.43%	-0.44%	-0.9%	-4.94%	-0.35%	-0.67%	-0.58%
FCF Growth %	10.79%	-1.23%	-0.17%	0.37%	0.1%	-1.07%	0.05%	0.66%	-0.72%	0.79%
FCF per Share	3.75	-0.86	-1.00	-0.58	-0.46	-0.80	-0.75	-0.25	-0.42	-0.09
FCF Conversion (FCF/Net Income)	-31.00x	-2.92x	0.99x	-10.67x	-1.68x	0.81x	1.11x	0.33x	4.30x	0.14x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-9.14%	15.98%	-56.22%	2.41%	-10.79%	-34.27%	-40.1%	-71.91%	-14.28%	-162.91%
Return on Invested Capital (ROIC)	-	-	-	64.86%	-77%	2.26%	-83.22%	-143.29%	-56.95%	-
Gross Margin	-67.02%	13.41%	-105.33%	12.94%	34.53%	28.76%	-184.12%	10.42%	10.83%	100%
Net Margin	-37.45%	22.51%	-148.28%	3.82%	-30.1%	-91.7%	-436.01%	-100.74%	-14.59%	-391.97%
Debt / Equity	0.05x	0.06x	0.07x	0.03x	0.09x	0.12x	0.41x	0.78x	0.77x	3.51x
Interest Coverage	-77.50x	61.06x	-353.83x	50.45x	-132.61x	3.16x	-153.29x	-199.39x	-19.80x	-91.12x
FCF Conversion	-31.00x	-2.92x	0.99x	-10.67x	-1.68x	0.81x	1.11x	0.33x	4.30x	0.14x
Revenue Growth	1874.2%	213.64%	-41.9%	144.83%	-13.67%	1.16%	-82.64%	376.17%	-10.01%	-75.68%

Frequently Asked Questions

Growth & Financials

Innate Pharma S.A. (IPHA) reported $34.0M in revenue for fiscal year 2024. This represents a 190% increase from $11.7M in 2011.

Innate Pharma S.A. (IPHA) saw revenue decline by 75.7% over the past year.

Innate Pharma S.A. (IPHA) reported a net loss of $80.1M for fiscal year 2024.

Dividend & Returns

Innate Pharma S.A. (IPHA) has a return on equity (ROE) of -162.9%. Negative ROE indicates the company is unprofitable.

Innate Pharma S.A. (IPHA) had negative free cash flow of $59.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Innate Pharma S.A. (IPHA) 10-Year Financial Performance & Capital Metrics

IPHA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $13M -75.7%
EBITDA -$50M -554.3%
Net Income -$49M -553.5%
EPS (Diluted) -0.61 -577.8%
Gross Margin 100% +823.7%
EBITDA Margin -392.85% -2590.6%
Operating Margin -408.64% -1574.1%
Net Margin -391.97% -2587.4%
ROE -162.91% -1041.1%
ROIC -
Debt/Equity 3.51 +356.5%
Interest Coverage -91.12 -360.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 3.6% through buybacks

✗Weaknesses

✗High debt to equity ratio of 3.5x
✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 28.8% over 5 years
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y30.12%

5Y-28.8%

3Y1.38%

TTM-61.2%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM6.28%

EPS CAGR

10Y-

5Y-

3Y-

TTM8.62%

ROCE

10Y Avg-14.17%

5Y Avg-22%

3Y Avg-29.7%

Latest-48.29%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	17.91M	56.16M	32.63M	79.89M	68.97M	69.77M	12.11M	57.67M	51.9M	12.62M
Revenue Growth %	18.74%	2.14%	-0.42%	1.45%	-0.14%	0.01%	-0.83%	3.76%	-0.1%	-0.76%
Cost of Goods Sold+	29.91M	48.63M	67M	69.56M	45.16M	49.71M	47M	51.66M	56.02M	0
COGS % of Revenue	1.67%	0.87%	2.05%	0.87%	0.65%	0.71%	3.88%	0.9%	1.08%	-
Gross Profit+	-12M	7.53M	-34.37M	10.34M	23.82M	20.07M	-22.3M	6.01M	5.62M	12.62M
Gross Margin %	-0.67%	0.13%	-1.05%	0.13%	0.35%	0.29%	-1.84%	0.1%	0.11%	1%
Gross Profit Growth %	-0.07%	1.63%	-5.56%	1.3%	1.3%	-0.16%	-2.11%	1.27%	-0.07%	1.25%
Operating Expenses+	28.68M	48.59M	72.61M	74.75M	50.87M	18.99M	25.52M	63.44M	18.29M	64.2M
OpEx % of Revenue	1.6%	0.87%	2.23%	0.94%	0.74%	0.27%	2.11%	1.1%	0.35%	5.09%
Selling, General & Admin	5.88M	9.33M	16.18M	19.25M	49.58M	18.99M	25.52M	14.47M	11.75M	11.93M
SG&A % of Revenue	0.33%	0.17%	0.5%	0.24%	0.72%	0.27%	2.11%	0.25%	0.23%	0.95%
Research & Development	29.91M	48.63M	67M	69.56M	1.6M	49.71M	47M	51.66M	56.02M	51.98M
R&D % of Revenue	1.67%	0.87%	2.05%	0.87%	0.02%	0.71%	3.88%	0.9%	1.08%	4.12%
Other Operating Expenses	-7.11M	-9.37M	-10.57M	-14.06M	-309K	-49.71M	-47M	-2.7M	-49.48M	283K
Operating Income+	-10.77M	7.57M	-39.98M	5.15M	-27.05M	1.08M	-47.83M	-57.42M	-12.67M	-51.58M
Operating Margin %	-0.6%	0.13%	-1.23%	0.06%	-0.39%	0.02%	-3.95%	-1%	-0.24%	-4.09%
Operating Income Growth %	0.46%	1.7%	-6.28%	1.13%	-6.26%	1.04%	-45.32%	-0.2%	0.78%	-3.07%
EBITDA+	-8.12M	10.83M	-35.59M	12.55M	-10.52M	13.3M	-43.23M	-12.02M	-7.58M	-49.58M
EBITDA Margin %	-0.45%	0.19%	-1.09%	0.16%	-0.15%	0.19%	-3.57%	-0.21%	-0.15%	-3.93%
EBITDA Growth %	0.54%	2.33%	-4.28%	1.35%	-1.84%	2.26%	-4.25%	0.72%	0.37%	-5.54%
D&A (Non-Cash Add-back)	2.65M	3.26M	4.4M	7.4M	16.53M	12.23M	4.6M	45.41M	5.09M	1.99M
EBIT	-6.57M	13.06M	-39.98M	5.15M	1.57M	1.08M	-47.83M	-57.68M	-6.93M	-48.91M
Net Interest Income+	-112K	686K	1.08M	1.3M	1.43M	223K	15K	258K	2.54M	1.87M
Interest Income	27K	0	1.25M	1.58M	1.62M	564K	327K	546K	3.18M	2.44M
Interest Expense	139K	124K	113K	102K	204K	341K	312K	288K	640K	566K
Other Income/Expense	4.07M	5.37M	-8.03M	-2.43M	6.29M	-1.91M	2.35M	-547K	5.1M	2.1M
Pretax Income+	-6.71M	12.94M	-48.02M	2.72M	-20.76M	-829K	-45.48M	-57.97M	-7.57M	-49.47M
Pretax Margin %	-0.37%	0.23%	-1.47%	0.03%	-0.3%	-0.01%	-3.75%	-1.01%	-0.15%	-3.92%
Income Tax+	0	301K	368K	-333K	206K	0	0	0	0	0
Effective Tax Rate %	1%	0.98%	1.01%	1.12%	1%	77.18%	1.16%	1%	1%	1%
Net Income+	-6.71M	12.64M	-48.38M	3.05M	-20.76M	-63.98M	-52.81M	-58.1M	-7.57M	-49.47M
Net Margin %	-0.37%	0.23%	-1.48%	0.04%	-0.3%	-0.92%	-4.36%	-1.01%	-0.15%	-3.92%
Net Income Growth %	0.66%	2.88%	-4.83%	1.06%	-7.81%	-2.08%	0.17%	-0.1%	0.87%	-5.54%
Net Income (Continuing)	-6.71M	12.64M	-48.38M	3.05M	0	-829K	-45.48M	-57.97M	-7.57M	-49.47M
Discontinued Operations	0	0	0	0	0	-63.16M	-7.33M	-131K	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.13	0.23	-0.89	0.05	-0.31	-0.01	-0.57	-0.73	-0.09	-0.61
EPS Growth %	0.67%	2.77%	-4.87%	1.06%	-6.97%	0.97%	-53.29%	-0.28%	0.88%	-5.78%
EPS (Basic)	-0.13	0.23	-0.89	0.05	-0.31	-0.01	-0.57	-0.73	-0.09	-0.61
Diluted Shares Outstanding	53.4M	53.87M	54.35M	58.78M	66.91M	78.93M	79.54M	79.64M	84.11M	81.05M
Basic Shares Outstanding	51.58M	53.87M	54.35M	58.78M	66.91M	78.93M	79.54M	79.59M	84.11M	81.05M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	252.13M	230.08M	137.52M	319.64M	237.6M	173.33M	138.26M	139.83M	148.01M	85.74M
Cash & Short-Term Investments	235.91M	197.69M	116.11M	167.53M	218.87M	151.64M	119.84M	101.48M	92.46M	80.77M
Cash Only	152.87M	175.91M	99.37M	152.31M	202.89M	136.79M	103.76M	84.22M	70.61M	66.4M
Short-Term Investments	83.04M	21.78M	16.74M	15.22M	15.98M	14.85M	16.08M	17.26M	21.85M	14.37M
Accounts Receivable	9.95M	25.55M	15.08M	146.64M	2.82M	11.33M	1.66M	3.14M	46.49M	1.64M
Days Sales Outstanding	202.78	166.08	168.72	669.94	14.9	59.25	50.02	19.88	326.94	47.52
Inventory	278K	513K	6.33M	0	5.6M	3.28M	0	0	0	0
Days Inventory Outstanding	3.39	3.85	34.47	-	45.26	24.1	-	-	-	-
Other Current Assets	0	0	0	0	4.92M	-860K	11.81M	27.88M	0	0
Total Non-Current Assets+	53.83M	51.5M	117.5M	131.57M	163.76M	134.09M	129.24M	68.03M	27.18M	25.32M
Property, Plant & Equipment	6.3M	9.09M	10.73M	10.22M	11.67M	11.69M	10.17M	8.54M	6.32M	5.13M
Fixed Asset Turnover	2.84x	6.18x	3.04x	7.82x	5.91x	5.97x	1.19x	6.75x	8.21x	2.46x
Goodwill	0	0	0	0	0	1K	2K	-41M	0	0
Intangible Assets	9.73M	9.07M	46.19M	84.53M	96.97M	46.29M	44.19M	42.55M	416K	0
Long-Term Investments	37.79M	32.98M	60.47M	35.18M	37.01M	38.93M	39.88M	35.12M	9.8M	10.28M
Other Non-Current Assets	37.79M	355K	111K	87K	16.83M	30.09M	29.97M	14.25M	1.64M	9.9M
Total Assets+	305.96M	281.58M	255.02M	451.22M	401.36M	307.42M	267.5M	207.86M	175.19M	111.06M
Asset Turnover	0.06x	0.20x	0.13x	0.18x	0.17x	0.23x	0.05x	0.28x	0.30x	0.11x
Asset Growth %	2.37%	-0.08%	-0.09%	0.77%	-0.11%	-0.23%	-0.13%	-0.22%	-0.16%	-0.37%
Total Current Liabilities+	60.16M	76.44M	73.91M	196.74M	121.82M	45.49M	79.89M	41.34M	39.64M	32.98M
Accounts Payable	8.62M	15.6M	19.97M	28.58M	27.94M	20.73M	14.73M	13.66M	8.56M	7.92M
Days Payables Outstanding	105.18	117.09	108.79	149.96	225.8	152.22	114.38	96.48	55.78	-
Short-Term Debt	150K	375K	429K	394K	1.49M	1.36M	29.94M	1.26M	8.45M	8.44M
Deferred Revenue (Current)	-1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	616K
Other Current Liabilities	10.01M	4.67M	4.69M	71.62M	42.99M	10.11M	21.91M	19.02M	7.82M	7.65M
Current Ratio	4.19x	3.01x	1.86x	1.62x	1.95x	3.81x	1.73x	3.38x	3.73x	2.60x
Quick Ratio	4.19x	3.00x	1.78x	1.62x	1.90x	3.74x	1.73x	3.38x	3.73x	2.60x
Cash Conversion Cycle	100.99	52.85	94.41	-	-165.63	-68.87	-	-	-	-
Total Non-Current Liabilities+	173.73M	118.97M	95.16M	87.24M	62.12M	104.75M	80.17M	112.37M	83.65M	69.24M
Long-Term Debt	1.35M	1.05M	2.42M	2.03M	14.1M	14.19M	11.49M	38.93M	30.61M	22.18M
Capital Lease Obligations	1.78M	3.01M	2.1M	1.14M	2.49M	2.76M	2.01M	1.22M	350K	104K
Deferred Tax Liabilities	0	2.55M	3.63M	1.56M	1.29M	7.09M	5.03M	8.57M	9.01M	0
Other Non-Current Liabilities	170.59M	112.35M	3.63M	14.4M	3.9M	49.25M	36.23M	55.74M	39.07M	44.13M
Total Liabilities	233.89M	195.41M	169.07M	283.98M	183.94M	151.45M	160.06M	153.71M	132.29M	102.22M
Total Debt+	3.75M	5.33M	5.86M	4.52M	18.72M	19.09M	44.25M	42.25M	39.89M	31M
Net Debt	-149.12M	-170.58M	-93.5M	-147.79M	-184.16M	-117.7M	-59.51M	-41.97M	-30.71M	-35.4M
Debt / Equity	0.05x	0.06x	0.07x	0.03x	0.09x	0.12x	0.41x	0.78x	0.77x	3.51x
Debt / EBITDA	-	0.49x	-	0.36x	-	1.43x	-	-	-	-
Net Debt / EBITDA	-	-15.74x	-	-11.78x	-	-8.85x	-	-	-	-
Interest Coverage	-77.50x	61.06x	-353.83x	50.45x	-132.61x	3.16x	-153.29x	-199.39x	-19.80x	-91.12x
Total Equity+	72.07M	86.17M	85.96M	167.24M	217.42M	155.97M	107.44M	54.15M	51.9M	8.83M
Equity Growth %	-0.03%	0.2%	-0%	0.95%	0.3%	-0.28%	-0.31%	-0.5%	-0.04%	-0.83%
Book Value per Share	1.35	1.60	1.58	2.85	3.25	1.98	1.35	0.68	0.62	0.11
Total Shareholders' Equity	72.07M	86.17M	85.96M	167.24M	217.42M	155.97M	107.44M	54.15M	51.9M	8.83M
Common Stock	2.69M	2.7M	2.88M	3.2M	3.94M	3.95M	3.98M	4.01M	4.04M	4.19M
Retained Earnings	-116.23M	-103.59M	-151.98M	-134.79M	-155.67M	-220.46M	-272.21M	-330.32M	-336.89M	-386.36M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-730K	-503K	180K	-1.1M	-472K	355K	456K	819K	495K	27K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	207.91M	-36.85M	-48.06M	-32.53M	34.92M	-51.81M	-58.46M	-19.15M	-32.56M	-6.9M
Operating CF Margin %	11.61%	-0.66%	-1.47%	-0.41%	0.51%	-0.74%	-4.83%	-0.33%	-0.63%	-0.55%
Operating CF Growth %	12.47%	-1.18%	-0.3%	0.32%	2.07%	-2.48%	-0.13%	0.67%	-0.7%	0.79%
Net Income	-6.71M	12.64M	-48.38M	3.05M	-20.76M	-63.98M	-52.81M	-58.1M	-7.57M	-49.47M
Depreciation & Amortization	2.65M	3.26M	4.39M	7.4M	16.53M	56.8M	4.6M	45.41M	5.09M	1.99M
Stock-Based Compensation	1.01M	1.03M	9.83M	2.71M	3.83M	2.48M	2.62M	4.25M	4.26M	3.94M
Deferred Taxes	-586K	-2.61M	3.17M	1.16M	-4.14M	2.65M	-1.68M	0	0	0
Other Non-Cash Items	47K	-383K	-88K	253K	-774K	-544K	-1.29M	1.8M	-2.24M	-2.52M
Working Capital Changes	211.49M	-50.79M	-16.98M	-47.1M	40.25M	-49.2M	-9.88M	-12.5M	-32.09M	39.16M
Change in Receivables	-6.14M	-16.17M	10.98M	-130.7M	110.3M	-22.92M	3.39M	-4.2M	-13.67M	0
Change in Inventory	0	0	0	0	0	25.38M	-6.27M	0	0	0
Change in Payables	9.23M	7.89M	4.39M	34.34M	1.39M	-6.53M	-946K	-7.66M	-3.89M	0
Cash from Investing+	-122.3M	60.51M	-29.46M	24.28M	-62.12M	-13.37M	-917K	1.88M	20.63M	9.2M
Capital Expenditures	-7.4M	-9.39M	-6.03M	-1.43M	-65.4M	-11.28M	-1.33M	-1.12M	-351K	-391K
CapEx % of Revenue	0.41%	0.17%	0.18%	0.02%	0.95%	0.16%	0.11%	0.02%	0.01%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	972K	-8.04M	-3.06M	46K	1.28M	912K	406K	-1K	-1.79M	1K
Cash from Financing+	3.03M	-602K	915K	61.22M	77.77M	-1.14M	26.82M	-1.83M	-1.97M	-6.01M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	3.36M	69K	378K	8K	-159K	-251K	187K	0	395K	2.93M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	200.51M	-46.24M	-54.09M	-33.96M	-30.48M	-63.09M	-59.79M	-20.28M	-34.91M	-7.29M
FCF Margin %	11.2%	-0.82%	-1.66%	-0.43%	-0.44%	-0.9%	-4.94%	-0.35%	-0.67%	-0.58%
FCF Growth %	10.79%	-1.23%	-0.17%	0.37%	0.1%	-1.07%	0.05%	0.66%	-0.72%	0.79%
FCF per Share	3.75	-0.86	-1.00	-0.58	-0.46	-0.80	-0.75	-0.25	-0.42	-0.09
FCF Conversion (FCF/Net Income)	-31.00x	-2.92x	0.99x	-10.67x	-1.68x	0.81x	1.11x	0.33x	4.30x	0.14x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-9.14%	15.98%	-56.22%	2.41%	-10.79%	-34.27%	-40.1%	-71.91%	-14.28%	-162.91%
Return on Invested Capital (ROIC)	-	-	-	64.86%	-77%	2.26%	-83.22%	-143.29%	-56.95%	-
Gross Margin	-67.02%	13.41%	-105.33%	12.94%	34.53%	28.76%	-184.12%	10.42%	10.83%	100%
Net Margin	-37.45%	22.51%	-148.28%	3.82%	-30.1%	-91.7%	-436.01%	-100.74%	-14.59%	-391.97%
Debt / Equity	0.05x	0.06x	0.07x	0.03x	0.09x	0.12x	0.41x	0.78x	0.77x	3.51x
Interest Coverage	-77.50x	61.06x	-353.83x	50.45x	-132.61x	3.16x	-153.29x	-199.39x	-19.80x	-91.12x
FCF Conversion	-31.00x	-2.92x	0.99x	-10.67x	-1.68x	0.81x	1.11x	0.33x	4.30x	0.14x
Revenue Growth	1874.2%	213.64%	-41.9%	144.83%	-13.67%	1.16%	-82.64%	376.17%	-10.01%	-75.68%

Frequently Asked Questions

Growth & Financials

Innate Pharma S.A. (IPHA) reported $34.0M in revenue for fiscal year 2024. This represents a 190% increase from $11.7M in 2011.

Innate Pharma S.A. (IPHA) saw revenue decline by 75.7% over the past year.

Innate Pharma S.A. (IPHA) reported a net loss of $80.1M for fiscal year 2024.

Dividend & Returns

Innate Pharma S.A. (IPHA) has a return on equity (ROE) of -162.9%. Negative ROE indicates the company is unprofitable.

Innate Pharma S.A. (IPHA) had negative free cash flow of $59.6M in fiscal year 2024, likely due to heavy capital investments.